U.S. Food and Drug Administration (FDA) accepts Bayer’s Elinzanetant – Non-Hormonal Treatment for Menopausal Symptoms
The recent New Drug Application (NDA) submission for elinzanetant marks an important development in non-hormonal treatments for vasomotor symptoms (VMS),…